On 6 January 2021, orphan designation EU/3/20/2390 was granted by the European Commission to Granzer Regulatory Consulting & Services, Germany, for rilonacept for the treatment of idiopathic pericarditis.
The sponsorship was transferred to Blue-Reg Pharma Consult, France in April 2022.
Treatment of idiopathic pericarditis
|Orphan designation status||
|EU designation number||
|Date of designation||
|August 2023||The sponsor's address was updated in August 2023.|
The sponsorship was transferred from Blue-Reg Pharma Consult, France to Yes Pharmaceutical Development Services GmbH, Germany
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: